Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

REPROS THERAPEUTICS INC. Form 8-K August 07, 2009

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2009
REPROS THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-15281 (Commission File Number) 76-0233274 (IRS Employer Identification No.)

2408 Timberloch Place, Suite B-7 The Woodlands, Texas 77380 (Address of principal executive offices and zip code) (281) 719-3400

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS

On August 6, 2009 Repros Therapeutics Inc. issued a press release titled Repros Therapeutics Inc. Announces That United States Food and Drug Administration Places Proellex® On Clinical Hold, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits.

99.1 Press Release, dated August 6, 2009.

Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REPROS THERAPEUTICS INC.

Dated: August 6, 2009 By: /s/ Louis Ploth, Jr.

Louis Ploth, Jr.

Chief Financial Officer

Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

EXHIBIT INDEX

Exhibit Number Description

99.1 Press Release, dated August 6, 2009.